Clinical trials
Kidney Transplant Infection clinical trials
Below are recruiting kidney transplant infection clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07368153RecruitingPhase 2
Preventing EBV infection after kidney transplant
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
Bern, Canton of BernAges 18 years+ - NCT06538961Recruiting
Immune registry for BK virus in kidney transplant patients
This study is creating a registry to learn how the immune system responds to BK virus in people who have recently received a kidney transplant from a deceased donor. Researchers hope this information will help improve treatment for BK virus infections.
Richmond, VirginiaAges 18 years+ - NCT06206486Recruiting
Gut germs and pain after kidney transplant
This study looks at whether the germs in your gut (microbiome) and certain chemicals in your blood affect pain after a kidney transplant. By joining, you may help doctors better understand and manage pain for future kidney transplant patients.
Chicago, IllinoisAges 18 years+ - NCT05597540RecruitingPhase 3
Shorter antibiotics for kidney transplant kidney infections
This study compares giving antibiotics for 7 days versus 14 days to treat acute kidney infections (pyelonephritis) in people with kidney transplants. It aims to see if the shorter course works just as well and is safer or easier to complete.
BordeauxAges 18 years+ - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT05365672RecruitingPhase 2
Donor immune cell therapy during live kidney transplant
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
BerlinAges 18–69 - NCT06474273RecruitingPhase 3
Treating T-cell rejection after kidney transplant
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Lambton, New South WalesAges 2 years+ - NCT05708508RecruitingPhase 3
Immune-guided vs universal medicine to prevent CMV after kidney transplant
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
RouenAges 18–75 - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
Boston, MassachusettsAges 18–70 - NCT07266467RecruitingPhase 4
Preventing CMV After First Kidney Transplant
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Xi'an, ShaanxiAges 18 years+ - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Birmingham, AlabamaAges 18–70 - NCT06972069RecruitingEarly Phase 1
Building tolerance to a new kidney with Sip-Tego
This study tests a new combination of medicines (Sip-Tego) to help your body accept a living donor kidney without needing lifelong anti-rejection drugs. It is for people with advanced kidney failure who are getting a first or second transplant.
Boston, MassachusettsAges 18–65 - NCT04128189RecruitingPhase 3
Shingrix vaccine for people waiting for a kidney transplant
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
Aurora, ColoradoAges 18–70 - NCT04494776Recruiting
Study of COVID-19 in kidney transplant patients
This study looks at what happens when people with kidney transplants get COVID-19. It may help improve how doctors monitor and manage COVID-19 in transplant recipients.
São Paulo, Aão PauloAges Any age - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+ - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT05711446Recruiting
Studying repeat urine leaks and bladder infections after kidney transplant
This study looks at how often kidney transplant patients get bladder infections after transplant, especially around routine follow-up visits. It may help the clinic find ways to lower infection risk after transplant.
New York, New YorkAges 18 years+ - NCT06013865RecruitingPhase 4
Empagliflozin for kidney transplant recipients
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
Hines, IllinoisAges 19 years+ - NCT06056102RecruitingPhase 1
CAR-T cell therapy to help highly sensitized kidney transplant patients
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
Boston, MassachusettsAges 18–65 - NCT06140537RecruitingPhase 4
Dapagliflozin for kidney and heart health after transplant
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
Aurora, ColoradoAges 18–80 - NCT06341543Recruiting
CMV blood test to guide treatment after organ transplant
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
Grenoble, MarylandAges 18 years+ - NCT06407232RecruitingPhase 3
Letermovir for CMV after kidney or pancreas transplant
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Madison, WisconsinAges 18 years+ - NCT06577805Recruiting
Robotic kidney transplant from living donors
This trial studies the results of kidney transplants using robotic surgery from living donors. It may help patients receive kidneys with potentially less impact from surgery.
Chengdu, SichuanAges 18–65 - NCT06591702Recruiting
Testing a quality-of-life questionnaire for kidney disease
This study tests a questionnaire (BETY-BQ) to see how well it measures quality of life in people with kidney disease, on dialysis, or after a kidney transplant. It will help doctors better understand your symptoms and daily life.
Ankara, AltındağAges 18 years+
Hear when a new Kidney Transplant Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for kidney transplant infection?
- Yes. Clin2 currently lists 113 recruiting kidney transplant infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.